US Stock MarketDetailed Quotes
TARS Tarsus Pharmaceuticals
- 26.850
- +3.240+13.72%
Close Aug 9 16:00 ET
- 26.850
- 0.0000.00%
Post 20:01 ET
1.02BMarket Cap-6020P/E (TTM)
28.000High25.350Low2.90MVolume27.000Open23.610Pre Close77.78MTurnover12.00%Turnover RatioLossP/E (Static)38.04MShares42.50052wk High4.05P/B649.51MFloat Cap12.57052wk Low--Dividend TTM24.19MShs Float63.690Historical High--Div YieldTTM11.22%Amplitude10.800Historical Low26.798Avg Price1Lot Size
Tarsus Pharmaceuticals Key Stats
Quarterly+Annual
YOY
| (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q4)Dec 31, 2022 | (Q3)Sep 30, 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenue | 40.81M | 1,004.56%27.61M | -32.42%17.45M | 30.76%13.08M | 1.87M | 0 | 363.82%2.5M | -54.73%25.82M | 2,858.58%10M | 0 |
| Operating revenue | --40.81M | 1,004.56%27.61M | -32.42%17.45M | 30.76%13.08M | --1.87M | --0 | 363.82%2.5M | -54.73%25.82M | 2,858.58%10M | --0 |
| Cost of revenue | 3M | 1.65M | 66.81%1.59M | 204.00%1.22M | 377K | 0 | 0 | -53.98%955K | 1,766.67%400K | 0 |
| Gross profit | 37.81M | 938.40%25.96M | -36.23%15.85M | 23.54%11.86M | 1.49M | 0 | 394.07%2.5M | -54.76%24.86M | 2,551.93%9.6M | 0 |
| Operating expense | 116.66%71.11M | 131.84%63.64M | 81.58%159.01M | 128.34%56.31M | 85.23%42.43M | 64.28%32.82M | 37.07%27.45M | 30.49%87.57M | 66.52%24.66M | 35.70%22.91M |
| Selling and administrative expenses | 189.97%58.79M | 241.67%51.58M | 141.83%108.7M | 193.89%43.01M | 152.83%30.32M | 95.40%20.28M | 89.98%15.1M | 76.99%44.95M | 116.08%14.63M | 79.79%11.99M |
| Research and development costs | -1.81%12.32M | -2.35%12.07M | 18.04%50.31M | 32.68%13.31M | 10.93%12.11M | 30.65%12.55M | 2.28%12.36M | 2.19%42.62M | 24.76%10.03M | 6.89%10.91M |
| Operating profit | -1.47%-33.3M | -51.03%-37.68M | -128.28%-143.16M | -195.13%-44.45M | -78.71%-40.94M | -528.27%-32.82M | -27.82%-24.95M | -415.85%-62.71M | -4.24%-15.06M | -45.85%-22.91M |
| Net non-operating interest income expense | 43.23%2.02M | 32.63%2.13M | 437.77%6.99M | 38.61%1.99M | 363.08%1.98M | 671.26%1.41M | 609.18%1.61M | 3,511.11%1.3M | 11,858.33%1.44M | 5,250.00%428K |
| Non-operating interest income | 85.53%4.13M | 35.94%3.12M | 195.43%10.34M | 40.01%2.98M | 167.67%2.84M | 649.49%2.23M | --2.29M | 9,619.44%3.5M | 17,625.00%2.13M | 13,162.50%1.06M |
| Non-operating interest expense | 155.15%2.01M | 44.89%949K | 56.25%3.23M | 44.71%958K | 40.55%825K | 44.67%787K | 107.28%655K | --2.06M | --662K | --587K |
| Total other finance cost | 260.71%101K | 17.24%34K | -10.37%121K | 3.33%31K | -28.26%33K | --28K | --29K | --135K | --30K | --46K |
| Other net income (expense) | -14,250.00%-2.01M | -138.16%-181K | 140.12%274K | 1,970.37%559K | -413.16%-195K | 94.85%-14K | 81.00%-76K | 58.63%-683K | 107.48%27K | 88.86%-38K |
| Gain on sale of security | -118.18%-6K | -858.54%-786K | 148.89%376K | 642.86%572K | -374.19%-147K | 108.73%33K | 81.24%-82K | 51.27%-769K | 121.63%77K | 91.04%-31K |
| Special income (charges) | ---1.94M | ---- | ---- | ---- | ---- | --0 | ---- | ---- | ---- | ---- |
| -Less:Other special charges | --1.94M | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- |
| Other non- operating income (expenses) | -25.53%-59K | 9,983.33%605K | -218.60%-102K | 74.00%-13K | -585.71%-48K | -144.34%-47K | -83.78%6K | 217.81%86K | -900.00%-50K | -240.00%-7K |
| Income before tax | -5.94%-33.29M | -52.57%-35.73M | -118.85%-135.89M | -208.13%-41.9M | -73.87%-39.15M | -447.17%-31.42M | -15.72%-23.42M | -350.88%-62.1M | 8.10%-13.6M | -40.39%-22.52M |
| Income tax | 0 | 0 | 0 | -107.27%-4K | 0 | 98.53%-5K | ||||
| Net income | -5.94%-33.29M | -52.57%-35.73M | -118.86%-135.89M | -208.13%-41.9M | -73.91%-39.15M | -447.17%-31.42M | -15.72%-23.42M | -349.06%-62.09M | 8.43%-13.6M | -43.41%-22.51M |
| Net income continuous Operations | -5.94%-33.29M | -52.57%-35.73M | -118.86%-135.89M | -208.13%-41.9M | -73.91%-39.15M | -447.17%-31.42M | -15.72%-23.42M | -349.06%-62.09M | 8.43%-13.6M | -43.41%-22.51M |
| Minority interest income | ||||||||||
| Net income attributable to the parent company | -5.94%-33.29M | -52.57%-35.73M | -118.86%-135.89M | -208.13%-41.9M | -73.91%-39.15M | -447.17%-31.42M | -15.72%-23.42M | -349.06%-62.09M | 8.43%-13.6M | -43.41%-22.51M |
| Preferred stock dividends | ||||||||||
| Other preferred stock dividends | ||||||||||
| Net income attributable to common stockholders | -5.94%-33.29M | -52.57%-35.73M | -118.86%-135.89M | -208.13%-41.9M | -73.91%-39.15M | -447.17%-31.42M | -15.72%-23.42M | -349.06%-62.09M | 8.39%-13.6M | -43.41%-22.51M |
| Basic earnings per share | 24.79%-0.88 | -14.77%-1.01 | -83.33%-4.62 | -167.35%-1.31 | -52.38%-1.28 | -387.50%-1.17 | 10.20%-0.88 | -276.12%-2.52 | 31.94%-0.49 | -10.53%-0.84 |
| Diluted earnings per share | 24.79%-0.88 | -14.77%-1.01 | -83.33%-4.62 | -167.35%-1.31 | -51.61%-1.28 | -387.50%-1.17 | 10.20%-0.88 | -276.12%-2.52 | 31.94%-0.49 | -11.09%-0.8443 |
| Dividend per share | ||||||||||
| Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
| Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
| Audit Opinions | -- | -- | Unqualified Opinion | -- | -- | -- | -- | Unqualified Opinion | -- | -- |
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
